What RES Group does

RES Group, Inc. is a privately held Quantitative Systems Pharmacology (QSP) services firm founded in 2001 as a spin-off from MIT and headquartered in Needham, Massachusetts. The company applies computational modeling — including translational PK/PD, physiologically-based pharmacokinetic (PBPK), and multiscale systems pharmacology models — to support drug development decisions from discovery through clinical stages and regulatory submission for pharmaceutical and biotechnology sponsors. Its service portfolio covers therapeutic areas including oncology, autoimmunity and inflammation, rare diseases, neuroscience, infectious disease, and toxicity, and spans modalities such as antibody-drug conjugates, gene therapies, monoclonal antibodies, T-cell engagers, cell therapies, and small molecules.

The firm assembles interdisciplinary teams of biologists, modelers, and project managers per engagement, structured in three phases (initiation/NDA-and-scoping, execution, and final regulatory report). RES Group reports a client base of over 50 pharmaceutical and biotechnology companies, a cumulative track record of 300+ projects across 100+ diseases, and an approximately 100% customer repeat rate. Notable regulatory outcomes attributed to RES-supported programs include the FDA approval of Takeda's ADZYNMA for congenital thrombotic thrombocytopenic purpura, Phase III clearance of Takeda's TAK-861 for narcolepsy, and multiple FDA IND clearances for gene therapy and immunology programs at Solid Biosciences, Astria Therapeutics, and Be Biopharma. The company is privately held with no disclosed funding rounds, ownership changes, or institutional investors; it is led by founder Glen Ko and Co-CEO John Tolsma.

The business model is professional services: engagements are scoped individually with custom deliverables, budgets, and timelines under multi-year contracts. Go-to-market is direct enterprise sales initiated through website contact or professional networks, supported by scientific thought leadership (peer-reviewed publications, conference presentations at ACoP/PAGE/EULAR, and case studies). The company does not sell software products, has no API or self-service channel, and prices via custom proposal rather than published rate cards. Marketing is concentrated on demonstrating technical credibility to a narrow audience of R&D decision-makers at pharma and biotech sponsors.

Name

RES Group

Legal name

RES Group, Inc.

Website

https://resgroupinc.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

RES Group is a privately held Quantitative Systems Pharmacology services firm, founded in 2001 as an MIT spin-off, that builds mechanistic PK/PD and PBPK models to support drug development and regulatory submissions for over 50 pharmaceutical and biotechnology sponsors across multiple therapeutic areas and modalities.

Ownership category

akta.pro rank

Product category

Quantitative Systems Pharmacology Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Quantitative systems pharmacology
• Model-informed drug development
• Pharmacokinetic modeling services
• Translational PK/PD modeling
• Regulatory submission modeling

Headquarters

HQ city

Needham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. QSP Modeling Services: RES Group provides model-informed drug development services to pharmaceutical and biotechnology companies. Revenue is generated through project-based consulting engagements. The engagement process follows a structured three-phase approach: Initiation (NDA, scope definition, proposal), Execution (model development, calibration, validation), and Final Phase (regulatory report delivery). The company reports ~100% customer repeat rate, indicating strong client retention and potential for recurring engagement.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

RES Group delivers Quantitative Systems Pharmacology (QSP) modeling and simulation services to pharmaceutical and biotechnology companies across drug discovery, preclinical, and clinical stages. Its interdisciplinary teams of biologists, modelers, and project managers build translational PK/PD, PBPK, and disease models to predict human dosing, optimize regimens, and support FDA regulatory submissions. Engagements follow a structured three-phase process (Initiation, Execution, Final Phase) producing model-informed drug development deliverables.

Product overview

RES Group is a Quantitative Systems Pharmacology (QSP) services company offering a unified portfolio of model-informed drug development services. The core offering is QSP Modeling Services, which encompasses Translational PK/PD Modeling, Physiologically-Based Pharmacokinetic (PBPK) Modeling, and FDA Regulatory Submission Support. These services are applied across therapeutic areas including Oncology, Rare Diseases, and Neuroscience, supporting drug modalities such as Antibody Drug Conjugates (ADC), gene therapies, monoclonal antibodies, and small molecules. The company operates as a consulting services firm rather than a software product company, providing scientific modeling expertise to pharmaceutical and biotechnology companies.

Differentiator

Problem solved

Functional benefit

Products and services

• QSP Modeling Services Core Quantitative Systems Pharmacology (QSP) modeling services applied across all stages of pharmaceutical development (Discovery, Pre-Clinical, Clinical), including drug design optimization, PK/PD modeling, efficacy prediction, safety/toxicity modeling, first-in-human dose prediction, and FDA regulatory submissions. Delivered to pharmaceutical and biotechnology companies.
• Translational PK/PD Modeling Translational pharmacokinetic/pharmacodynamic modeling that integrates in vitro data, preclinical tumor growth inhibition data, and target-mediated drug disposition (TMDD) with allometric scaling to predict human pharmacokinetics and tumor response for first-in-human clinical trial dose selection. Intended for pharmaceutical and biotechnology drug development teams.
• Physiologically-Based Pharmacokinetic (PBPK) Modeling Mechanistic PBPK models describing intracellular trafficking, FcRn recycling, nonspecific clearance, and target binding to predict monoclonal antibody pharmacokinetics from in vitro data, including half-life extension and catch-and-release properties. Designed for biologic and monoclonal antibody developers.
• FDA Regulatory Submission Support Model-informed drug development services supporting FDA regulatory submissions, IND applications, and regulatory decision-making by generating human dose predictions and quantitative evidence packages that move programs through critical regulatory milestones.
• Oncology QSP Modeling Therapeutic-area QSP modeling for oncology indications including NSCLC, SCLC, ALL, NHL, AML, colorectal cancer, breast cancer, and pancreatic cancer, supporting drug development for ADCs, T-cell engagers, and small molecule inhibitors across sponsors' oncology pipelines.
• Rare Disease QSP Modeling QSP modeling services for rare diseases including Gaucher disease, Fabry disease, Hemophilia, Huntington's disease, and hereditary angioedema (HAE), supporting gene therapy and enzyme replacement therapy development programs.
• Gene Therapy QSP Modeling QSP modeling services for adeno-associated virus (AAV)-based gene therapies, including translational frameworks for Factor IX expression in hemophilia B and CNS tissue distribution modeling for gene therapy programs.
• Antibody Drug Conjugate (ADC) QSP Modeling Multiscale systems pharmacology models for ADC development, including bispecific antibody-drug conjugates such as MUC1-EGFR (M1231), integrating in vitro internalization data, tumor growth inhibition, and target-mediated drug disposition to inform first-in-human dose selection.

Quantifiable outcome

• ~100% customer repeat rate indicating exceptional client satisfaction
• +4 more outcomes

Named customers12 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• TakedacoreStrategic or Co-development PartnerTakeda is a major pharmaceutical company and client of RES Group. RES supported the development of ADZYNMA (ADAMTS13) which received FDA approval as the first and only FDA-approved recombinant protein for congenital thrombotic thrombocytopenic purpura. RES also supported Takeda's TAK-861 program for narcolepsy which received FDA clearance for Phase 3 trial.
• Solid BiosciencescoreStrategic or Co-development PartnerSolid Biosciences is a biotechnology company focused on Duchenne Muscular Dystrophy. RES supported regulatory submissions for multiple gene therapy programs including SGT-003 (DMD), SGT-212 (Friedreich's Ataxia), and SGT-501 (CPVT), achieving multiple FDA IND clearances.
• Astria TherapeuticscoreStrategic or Co-development PartnerAstria Therapeutics is developing antibody therapies for allergic and immunological diseases. RES supported FDA IND clearances for STAR-0215 (hereditary angioedema) and STAR-0310 (atopic dermatitis) programs.
• EMD SeronocoreStrategic or Co-development PartnerEMD Serono (Merck KGaA's US biopharma business) partnered with RES for M9140, an anti-CEACAM5 antibody-drug conjugate for advanced solid tumors that received FDA Phase I trial clearance.
• Be BiopharmacoreStrategic or Co-development PartnerBe Biopharma is developing engineered B-cell medicines. RES supported the FDA IND clearance for BE-101, an engineered B-cell medicine for Hemophilia B.
• Lifordi ImmunotherapeuticsminorStrategic or Co-development PartnerLifordi Immunotherapeutics is developing glucocorticoid antibody-drug conjugates for autoimmune diseases. RES provided QSP modeling support for LFD-200, with preclinical data presented at EULAR 2025.
• PfizercoreStrategic or Co-development PartnerPfizer, one of the world's largest pharmaceutical companies, has engaged RES Group for QSP modeling services across various drug development programs.
• SanoficoreStrategic or Co-development PartnerSanofi, a global pharmaceutical company, has collaborated with RES Group on QSP modeling projects for drug development programs.
• GenentechcoreStrategic or Co-development PartnerGenentech, a biotechnology pioneer and member of Roche group, has worked with RES Group on QSP modeling services.
• AstraZenecacoreStrategic or Co-development PartnerAstraZeneca has engaged RES Group for QSP modeling support across drug development programs.
• Vertex PharmaceuticalscoreStrategic or Co-development PartnerVertex Pharmaceuticals, focused on cystic fibrosis and other diseases, has collaborated with RES Group on QSP modeling projects.
• Eli LillycoreStrategic or Co-development PartnerEli Lilly has engaged RES Group for QSP modeling services across various therapeutic areas.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Applied BioMath: QSP and mechanistic modeling services firm focused on pharmaceutical R&D, with similar customer profiles to RES Group. Competes for the same model-informed drug development engagements from biotech and mid-sized pharma.
• Metrum Research Group: Quantitative pharmacology services firm offering PK/PD, QSP, and pharmacometrics consulting. Overlaps with RES Group's model-informed drug development work, particularly for sponsors seeking population and disease modeling expertise.
• In Silico Biosciences: Quantitative systems pharmacology and mechanism-based modeling consultancy serving pharma R&D. Closely comparable to RES Group's niche QSP offering, with similar project-based engagements and therapeutic-area scope.
• Pharmetheus: European-based QSP, PBPK, and pharmacometrics consultancy serving pharma R&D. Closely comparable to RES Group's service portfolio and customer use cases, with similar scientific depth and a services-only model.
• Rosa & Co: Specialist QSP and PhysioPD consulting firm serving pharmaceutical and biotech clients. Directly comparable to RES Group in offering, therapeutic-area coverage, and customer base.
• Certara: The largest dedicated provider of model-informed drug development (MIDD) services and biosimulation software. Directly competes with RES Group in PBPK/QSP consulting while also offering broader regulatory and clinical pharmacology services across pharma and biotech.
• Simulations Plus: Provides PBPK/QSP modeling software (GastroPlus, MonolixSuite, Immunetrics) and services for pharma R&D. Overlaps directly with RES Group's mechanistic modeling offering but differentiates through its software-led, asset-light model.

Broad incumbents

• Evidera (PPD / Thermo Fisher): A large CRO-owned provider of real-world evidence, HEOR, and modeling services. Overlaps with RES Group in model-based evidence generation and regulatory support, but operates at much broader scale and within a wider R&D services portfolio.
• Schrödinger: Physics-based computational platform serving pharma discovery and development. Overlaps with RES Group in computational modeling for drug R&D but is primarily a software platform serving earlier-stage discovery use cases.

Emerging players

• GNS Healthcare: AI-driven causal machine learning platform for drug discovery and development. Comparable to RES Group as a model-informed R&D partner for pharma, but takes a data-centric rather than first-principles mechanistic approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RES Group